Skip to content

Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety

Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06126601
Acronym
HYPPO
Enrollment
150
Registered
2023-11-13
Start date
2023-07-18
Completion date
2027-03-01
Last updated
2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperamylasemia, Pancreatectomy, Pancreatitis, Acute

Brief summary

Recent evidence suggests that postoperative hyperamylasemia (POH) is a predictor of morbidity after pancreatectomy. This is based on the assumption that pancreatitis after pancreatectomy (PPAP) is a major trigger for the development of complications and is indicated by hyperamylasemia. Standardized prospective analysis and correlation with other laboratory parameters, hasn't been performed to date. Therefore the overall study aims are: * To prospectively evaluate the incidence and assess the clinical value of biochemical changes for the postoperative course. * To confirm and improve the definition and classification of postpancreatectomy acute pancreatitis (PPAP) of the International Study Group of Pancreatic Surgery (ISGPS) and to provide knowledge for effective early management of complications.

Interventions

OTHERPancreatectomy

Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed. Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels.

Sponsors

Technische Universität Dresden
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* All patients undergoing pancreatic resection for malignant and benign disease with or without pancreatic anastomosis * Patients aged 18-85 years * Willingness to participate as demonstrated by giving a written informed consent.

Exclusion criteria

* Necrosectomy (endoscopic or open) for primary acute pancreatitis or within laparotomy * Age less than 18 years * Surgical drainage procedures without pancreatic resection (cystojejunostomy for pancreatic pseudocysts) * One-stage total pancreatectomy * Missing written consent

Design outcomes

Primary

MeasureTime frameDescription
Incidence of PPAP (Postpancreatectomy Acute Pancreatitis)90 days after surgeryIncidence after pancreasresection (pancreatoduodenectomy and distal pancreas resection) according to the definition of ISGPS (International Study Group on Pancreatic Surgery)
Significance of biochemical changes (postoperative hyperamylasemia and hyperlipasemia)90 days after surgeryCorrelation with postoperative complications according to the Clavien-Dindo classification and Comprehensive Complication Index ( CCI)

Secondary

MeasureTime frameDescription
Correlation between hyperamylasemia and rescue pancreatectomy after pancreatoduodenectomy90 days after surgeryIncidence of rescue pancreatectomy after pancreatoduodenectomy with postoperative hyperamylasemia
Correlation between hyperamylasemia and radiological findings for pancreatitis90 days after surgeryIncidence of pancreatitis according to the CT scan postoperatively
Incidence of postoperative mortality90 days after surgeryPostoperative death after complications

Countries

Germany

Contacts

CONTACTOlga Radulova-Mauersberger, Dr. med.
studienzentrum-vtg@ukdd.de+49 351 458-0
PRINCIPAL_INVESTIGATORMarius Distler, Prof. Dr.

University Hospital Dresden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026